{"title":"Regeneron期待Avalanche的Ocular BioFactory™作为潜在的Eylea®继任者","authors":"Heather Cartwright","doi":"10.3833/PDR.V2014I6.2036","DOIUrl":null,"url":null,"abstract":"In order to strengthen its ophthalmology pipeline and defend its Eylea® (aflibercept) franchise in the long term, Regeneron Pharmaceuticals has partnered with Avalanche Biotechnologies to develop and commercialise next-generation gene therapies for ophthalmologic diseases using Avalanche’s adeno-associated virus (AAV)-based Ocular BioFactory™ platform. The collaboration covers up to eight different targets and provides Regeneron with a time-limited right of first negotiation for certain rights to Avalanche’s lead asset AVA-101, which is in Phase IIa development for wet age-related macular degeneration.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"81 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2014-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Regeneron Looks to Avalanche’s Ocular BioFactory™ for Potential Eylea® Successor\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2014I6.2036\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In order to strengthen its ophthalmology pipeline and defend its Eylea® (aflibercept) franchise in the long term, Regeneron Pharmaceuticals has partnered with Avalanche Biotechnologies to develop and commercialise next-generation gene therapies for ophthalmologic diseases using Avalanche’s adeno-associated virus (AAV)-based Ocular BioFactory™ platform. The collaboration covers up to eight different targets and provides Regeneron with a time-limited right of first negotiation for certain rights to Avalanche’s lead asset AVA-101, which is in Phase IIa development for wet age-related macular degeneration.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"81 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-03-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2014I6.2036\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2014I6.2036","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Regeneron Looks to Avalanche’s Ocular BioFactory™ for Potential Eylea® Successor
In order to strengthen its ophthalmology pipeline and defend its Eylea® (aflibercept) franchise in the long term, Regeneron Pharmaceuticals has partnered with Avalanche Biotechnologies to develop and commercialise next-generation gene therapies for ophthalmologic diseases using Avalanche’s adeno-associated virus (AAV)-based Ocular BioFactory™ platform. The collaboration covers up to eight different targets and provides Regeneron with a time-limited right of first negotiation for certain rights to Avalanche’s lead asset AVA-101, which is in Phase IIa development for wet age-related macular degeneration.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
